PRKD3: Protein Kinase D3 – A Key Signaling Mediator in Cell Growth and Cancer
Comprehensive genomic and proteomic overview of PRKD3, including expression, mutations, and disease associations.
Gene Information Card
| Symbol | PRKD3 |
|---|---|
| Full Name | Protein Kinase D3 |
| Gene Type | Protein coding |
| Chromosomal Location | 2p21 |
| NCBI Gene ID | 23683 ncbi.nlm.nih.gov/gene/23683 |
| Ensembl ID | ENSG00000115944 |
| UniProt ID | O94806 |
| OMIM ID | 605307 |
| HGNC ID | 9398 |
| Aliases | PKD3, nPKC-NU, PKC-NU, PRKCN |
Description
PRKD3 (protein kinase D3) is a member of the protein kinase D (PKD) family of serine/threonine kinases. It is involved in signal transduction pathways regulating cell proliferation, differentiation, migration, and vesicle trafficking. PRKD3 is activated by diacylglycerol (DAG) and protein kinase C (PKC) and plays a role in cancer progression, immune response, and cardiac function.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast Cancer | PRKD3 overexpression promotes cell proliferation and migration via MAPK/ERK signaling | COSMIC, PMID: 25605247 |
| Pancreatic Cancer | PRKD3 enhances invasion and metastasis through regulation of MMPs | COSMIC, PMID: 23943757 |
| Prostate Cancer | PRKD3 knockdown reduces tumor growth and induces apoptosis | COSMIC, PMID: 27149991 |
| Cardiac Hypertrophy | PRKD3 mediates hypertrophic signaling in cardiomyocytes | PMID: 20089855 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Heart | 12.3 | Medium |
| Brain | 8.7 | Low |
| Lung | 15.2 | Medium |
| Liver | 6.1 | Low |
| Pancreas | 18.9 | Medium |
| Breast | 22.4 | High |
| Prostate | 20.1 | High |
| Colon | 14.5 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 28.6 | High expression |
| PANC-1 (pancreatic cancer) | 32.1 | High expression |
| PC3 (prostate cancer) | 25.3 | High expression |
| HEK293 (embryonic kidney) | 12.4 | Moderate expression |
| HeLa (cervical cancer) | 18.7 | Moderate expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1234G>A (p.Glu412Lys) | Missense | 0.02% | Unknown functional impact |
| c.567_568insC (p.Leu190Profs*5) | Frameshift | 0.01% | Loss of function |
| c.890A>G (p.Asn297Ser) | Missense | 0.03% | Gain of function (predicted) |
| c.1456C>T (p.Arg486Trp) | Missense | 0.01% | Unknown |
Mutation functional classification
Loss of Function (LOF)
Frameshift mutations (e.g., p.Leu190Profs*5) lead to truncated, non-functional kinase domain.
Gain of Function (GOF)
Missense mutations such as p.Asn297Ser may enhance kinase activity, promoting oncogenic signaling.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported in PRKD3.
View complete mutation data：
Gene Ontology (GO)
Pathways
• MAPK signaling pathway (Reactome: R-HSA-5683057)
• VEGF signaling pathway (KEGG: hsa04370)
• DAG/PKC signaling (Reactome: R-HSA-114608)
• Regulation of actin cytoskeleton (KEGG: hsa04810)
Protein Summary
PRKD3 encodes a 912-amino acid serine/threonine kinase with a catalytic domain, two cysteine-rich zinc finger domains (C1a and C1b), and a pleckstrin homology (PH) domain. It is activated by DAG and PKC, localizes to the Golgi and plasma membrane, and regulates cell survival, motility, and secretion. Overexpression in cancers correlates with poor prognosis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRKD3 Knockout HEK293 Cell Line | EDJ-KQ1312 | Human | 23683 | Details Get a Quote |
| PRKD3 Knockout HeLa Cell Line | EDJ-KQ19390 | Human | 23683 | Details Get a Quote |
| PRKD3 Knockout A-549 Cell Line | EDJ-KQ20734 | Human | 23683 | Details Get a Quote |
| PRKD3 Knockout HCT 116 Cell Line | EDJ-KQ20735 | Human | 23683 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
